Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Kraken Zone Discovery Unlocks Significant Value (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News MediciNova Inc MNOV

Healthcare Biotechnology
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple... see more

Recent & Breaking News (NDAQ:MNOV)

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

GlobeNewswire January 29, 2026

2026 New Year's Greetings from the CEO

GlobeNewswire January 6, 2026

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

GlobeNewswire December 18, 2025

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

GlobeNewswire December 8, 2025

Message from the CEO to MediciNova Shareholders

GlobeNewswire December 1, 2025

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

GlobeNewswire November 18, 2025

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

GlobeNewswire November 6, 2025

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire November 4, 2025

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

GlobeNewswire October 30, 2025

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

GlobeNewswire October 6, 2025

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

GlobeNewswire September 22, 2025

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

GlobeNewswire September 16, 2025

MediciNova Provides Shareholder Update on Key Developments

GlobeNewswire September 8, 2025

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 3, 2025

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

GlobeNewswire August 26, 2025

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

GlobeNewswire July 31, 2025

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

GlobeNewswire July 24, 2025

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

GlobeNewswire April 14, 2025

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

GlobeNewswire April 8, 2025

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

GlobeNewswire December 5, 2024

Podcasts